Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR

Sichuan Kelun-Biotech (SKBBY) shows no detected cyber incidents or red-flag 8-K filings in our 90-day monitoring window, indicating baseline operational stability over this recent period. However, zero detected events in a short window does not eliminate structural risk; the company operates in a capital-intensive biopharmaceutical sector where dilution, financing dependency, and regulatory exposure are material. The full $49 Report extends analysis to 12 months of SEC filings, quantifies dilution risk and equity raise patterns, contextualizes any 8-K history, and flags AI-detected anomalies in disclosure consistency. The full $49 Report adds comprehensive financing history, dilution trajectory scoring, and 12-month event context.